Shares of Arena Pharmaceuticals Inc. jumped 17.4 percent Friday on news of an expanded alliance with Eisai Inc. for obesity drug Belviq (lorcaserin), a deal that brings $60 million up front and aims to advance the drug into new commercial markets and possibly new indications.